TABLE 3.

Aberrantly methylated genes that play an important role in both diagnosis and prognosis of GC.

SFRP2
Detection	Sensitivity: 60.9%; Specificity: 86.0% (plasma) Miao et al. (2020)
	Sensitivity: 22.7%; Specificity: 90.0% (stool) Guo et al. (2021)
Prognosis	Shorter PFS (HR = 13.05; 95% CI = 3.05–55.95) and OS (HR = 7.80; 95% CI = 1.81–33.60) (stage III); Shorter PFS (HR = 2.74; 95% CI = 1.58–4.78) and OS (HR = 3.14; 95% CI = 1.67–5.92) (stage IV) (serum) Yan et al. (2021)
THBS1
Detection	Sensitivity: 63.4%; Specificity: 94.2% (serum) Wang et al. (2015)
Prognosis	Worse DFS (HR = 3.838; 95% CI = 1.691–8.710; p = 0.001) (serum) Hu X. et al. (2021)
	Worse OS survival (p = 0.0483) (serum) Wang et al. (2015)
UCHL1
Detection	Sensitivity: 56.1%; Specificity: 89.5% (serum) Wang et al. (2015)
Prognosis	Worse OS (p = 0.033) (serum) Wang et al. (2015)
SOX17
Detection	Sensitivity: 58.9%; Specificity: 100% (serum) Balgkouranidou et al. (2013)
Prognosis	Lower PFS and OS (p < 0.001) (plasma) Karamitrousis et al. (2021)
APC
Detection	Sensitivity: 17%; Specificity: 100% (serum) Leung et al. (2005)
Prognosis	Poorer OS (HR = 4.6, 95% CI = 1.1–20.3, p = 0.046) (serum) Balgkouranidou et al. (2015)
E-cadherin
Detection	Sensitivity: 13%; Specificity: 100% (serum) Leung et al. (2005)
	Sensitivity: 57.4%; Specificity: 100% (serum) Lee et al. (2002)
Prognosis	Poorer 3-years survival rate (p < 0.05) (serum) Ikoma et al. (2006)
RASSF1A
Detection	Sensitivity: 34%; Specificity: 100% (serum) Wang et al. (2008)
Prognosis	Lower OS (HR = 2.33, 95% CI = 1.14–4.85, p = 0.002) (plasma) Pimson et al. (2016)
	Lower PFS and OS (p = 0.004) (plasma) Karamitrousis et al. (2021)
RNF-180
Detection	Sensitivity: 56%; Specificity: 100% (plasma) Cheung et al. (2012)
Prognosis	Poorer OS (HR = 2.13; 95% CI = 1.11–4.08; p = 0.02) (plasma) Cheung et al. (2012)
SPG20
Detection	Sensitivity: 48.8%; Specificity: 100% (whole blood) Zhang et al. (2014)
Prognosis	Shorter OS (p = 0.037) (whole blood) Zhang et al. (2014)